Raymond Richman - Jesse Richman - Howard Richman
Richmans' Trade and Taxes Blog
Here's a selection:
Click here to read it on the American Thinker website.
Fauci time and the Coronavirus Vaccine - I'm published in American Thinker
The American vaccine’s Phase 1 clinical trials are bogged down. They began on March 3 and are not scheduled to end until June 1, 2021.
Why fifteen months for the first American vaccine’s clinical trials? The reason is simple. Dr. Anthony Fauci, the director of NIAID (National Institute of Allergy and Infectious Diseases), is conducting them in Fauci Time. (Fauci is also conducting the clinical trials to see if Remdesivir is effective against COVID-19 in Fauci Time – those trials are not scheduled to end until April 1, 2023.)
Normally, during a health emergency, the U.S. gets out a vaccine within months. Take the H1N1 (Swine Flu) pandemic of 2009. The CDC has published a timeline:
So, in 2009, the FDA started its clinical trials of a vaccine on July 22 and approved four vaccines seven weeks later. Meanwhile, in 2019, Fauci’s NIAID started its clinical trials on March 3 and plans to take 15 months to complete them.
U.S. regulations allow for two rapid approval processes for vaccines during a health emergency. One of them, called Accelerated Approval, is the process used to approve the H1N1 vaccines after less than two months of clinical trials. The other, called Emergency Use Authorization, is the process used to approve the anthrax vaccine so that it could be administered to the soldiers invading Iraq.
In the Accelerated Approval process, a single clinical trial phase determines whether the vaccine is safe and whether it creates the required antibodies. In vaccine terminology, these pathogen-specific antibodies are considered to be a “surrogate endpoint,” permitting the vaccine to be approved for use without field studies. For such vaccines, there is a “Phase 4” process during which the success of the vaccine is continuously monitored while it is being used.
The following are among the successful vaccines approved through the Accelerated Approval process:...
Click here to read it on the American Thinker website
Testing Hydroxychloroquine as a Prophylactic -- I'm published in this morning's American Thinker
There are three experiments getting started now that will determine whether hydroxychloroquine (HCQ) works as a prophylactic. A prophylactic functions almost like a vaccine, except that it has to be taken daily.
All three experiments are the type that researchers dream about. They are called double-blind studies because neither the subjects nor the people working with the subjects will know which subjects are taking an HCQ pill and which are taking a placebo pill. Both pills will look identical.
The subjects of all three experiments will be healthcare workers and/or first responders. The experimenters will follow the subjects closely to determine which ones catch COVID-19. All three experiments are being conducted by reputable top-notch institutions:...
To read it on the American Thinker website, go to:
State restrictions on the use of HCQ
I've gone through two websites (one published by the National Academy for State Health Policy and the other published by the American Medical Association) and have classified state restrictions regarding use of HCQ (hydroxychloroquine) to treat COVID-19. I have classified those state policies into three groups:
Others may look at the same charts and classify the states differently. The rules regarding Pharmacy Discretion and Prophylaxis are largely to prevent shortages from occurring in the event that there is not enough to go around. The Legal Restrictions appear to be designed to prevent primary care physicians from prescribing HCQ based upon symptoms. In this posting, I will just discuss the states that have legal restrictions:
And here's a table showing the deaths per case and deaths per million people in the states with legal restrictions, as compared to the national average of all 50 states:...
Lots of studies of HCQ - none of which use zinc
We will soon know whether HCQ (hydroxychloroquine) works by itself (none include zinc with the HCQ). I just searched clinicaltrials.gov. Eight new studies are testing the effectiveness of HCQ against COVID-19:
Deborah Birx: 1 million Abbott Lab tests not being used.
See this video from Wednesday's Coronavirus task force briefing at the 1:38:35 mark:
Detroit hospital system starts test of HCQ as Prophylactic
President Trump isn't the only one who is bypassing the Washington bureaucracy in an attempt to find a solution to COVID-19. The Henry Ford Health System in Detroit has announced the WHIP COVID-19 study to find out whether HCQ (hydroxychloroquine) works as a prophylactic. They are now asking for volunteers among healthcare workers and first responders, people who are likely to come into contact with those who are sick from the virus. It will be a randomized, double blinded study, and the first results will become available about 4 weeks after the experiment begins -- probably around June 1.
They started the study in response to a request from Detroit's mayor and local health care experts, according to their April 2 press release:...
The South Korean solution to the COVID-19 virus (widespread testing and the hydroychloroquine-zinc cure) is beginning to work in the United States. Americans, like South Koreans, will soon be back at work and school. But at Monday's Coronavirus Task Force press briefing, Dr. Anthony Fauci ignored the success. Instead, he pretended that the only way the U.S. could get back to normal was through vaccines and new therapies. He was responding to a question directed to him by reporter Jonathan Karl at the 37:37 mark of this video:
Fauci was being disingenuous. His own organization NIAID (one of the institutes of NIH) is slow-walking both therapies and vaccines. For example, NIAID is currently conducting a study on the effectiveness of Remdesivir, a drug which, along with chloroquine and hydroxychloroquine, proved effective against COVID-19 in the Chinese test-tube studies. Here's NIAID's schedule for completing Phase 3 of its approval process:
Believe it or not, that is not a misprint! Fauci was touting new therapies even while his own organization was slow walking the most promising of them so that it would not be ready until 2023!
The same is true of vaccines....
[Click here to read it on the American Thinker website.]
The solution to COVID-19 is in Sight! - we're published in today's American Thinker
The solution to COVID-19 is in Sight! It is the South Korean solution: (1) widespread testing, and (2) treatment at home using a hydroxychloroquine-zinc cocktail.
The South Korea solution works! People there are back at work. The death ratios (deaths/recoveries; deaths/cases) are low. Unfortunately, the bureaucrats in the U.S. health bureaucracy are trying to stop it from happening in the United States. See the commentary that my son and I wrote in today’s American Thinker:
Journal of Economic Literature:
Atlantic Economic Journal: